Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas

Sarah J. Storr(Nottingham University Hospitals NHS Trust), Stewart G. Martin(University of Nottingham), Jillian Davis(Nottingham University Hospitals NHS Trust), Alexander M. Reece-Smith(Nottingham University Hospitals NHS Trust), Xuan Pu(Nottingham University Hospitals NHS Trust), Dileep N. Lobo(Nottingham University Hospitals NHS Trust), Simon L. Parsons(Galapagos (Belgium)), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)
Journal of Gastroenterology
January 18, 2013
10.1007/s00535-012-0743-4
Cited by 20

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations
|World Journal of Surgery|2016|607
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374